Inhibitex announced that it has initiated a Phase 2 trial with FV-100, its once-daily, oral antiviral compound in development for the treatment of herpes zoster (shingles). This trial is a well-controlled, double-blind study evaluating FV-100 against an active control (valacyclovir) in approximately 350 patients who are ≥50 years of age. Trial objectives include the evaluation of the safety and therapeutic benefit of FV-100 in reducing: the severity and duration of shingles-related acute pain; the incidence of post herpetic neuralgia (PHN); the time to lesion healing; and the use of concomitant pain medications.
FV-100 is an orally-available bicyclic nucleoside analogue that inhibits replication of varicella zoster virus (VZV).
For more information call (678) 746-1100 or visit www.inhibitex.com.